The therapeutic potential of chemical chaperones in protein folding diseases

Prion

Volumn 8, Issue 2, 2014, Pages 197-202

  Cortez, Leonardo ^a   Sim, Valerie ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Chemical chaperones; DCA; Osmolytes; PBA; Protein folding diseases; Protein misfolding; TUDCA; UDCA

Indexed keywords

4 PHENYLBUTYRIC ACID; ALPHA SYNUCLEIN; AMINO ACID; AMINO ACID DERIVATIVE; AMYLOID PRECURSOR PROTEIN; BILE ACID; CHAPERONE; DEOXYCHOLIC ACID; G PROTEIN COUPLED RECEPTOR; HISTONE DEACETYLASE; LIPID; PREALBUMIN; PRION PROTEIN; TREHALOSE; TRIMETHYLAMINE OXIDE; URSODEOXYCHOLIC ACID; VORINOSTAT;

AMNESIA; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; FAMILIAL AMYLOID POLYNEUROPATHY; FAMILIAL CREUTZFELDT JAKOB DISEASE; HUMAN; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; NERVE CELL PLASTICITY; NONHUMAN; PRION DISEASE; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN STRUCTURE; REVIEW; THERAPY EFFECT; CHEMISTRY; CLINICAL TRIAL (TOPIC); METABOLISM; NEURODEGENERATIVE DISEASES; TRANSLATIONAL RESEARCH;

CLINICAL TRIALS AS TOPIC; HUMANS; MOLECULAR CHAPERONES; NEURODEGENERATIVE DISEASES; PROTEIN FOLDING; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84907560795     PISSN: 19336896     EISSN: 1933690X     Source Type: Journal    
DOI: 10.4161/pri.28938     Document Type: Review

References (64)

1. Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 2013; 501:45-51; PMID:24005412; http://dx.doi.org/10.1038/nature12481
2. Doyle SM, Genest O, Wickner S. Protein rescue from aggregates by powerful molecular chaperone machines. Nat Rev Mol Cell Biol 2013; 14:617-29; PMID:24061228; http://dx.doi.org/10.1038/nrm3660
3. Muchowski PJ, Wacker JL. Modulation of neuro-degeneration by molecular chaperones. Nat Rev Neurosci 2005; 6:11-22; PMID:15611723; http://dx.doi.org/10.1038/nrn1587
4. Turturici G, Sconzo G, Geraci F. Hsp70 and its molecular role in nervous system diseases. Biochem Res Int 2011; 2011:618127; PMID:21403864; http://dx.doi.org/10.1155/2011/618127
5. Nemirovsky A, Fisher Y, Baron R, Cohen IR, Monsonego A. Amyloid beta-HSP60 peptide conjugate vaccine treats a mouse model of Alzheimer's disease. Vaccine 2011; 29:4043-50; PMID:21473952; http://dx.doi.org/10.1016/j.vaccine.2011.03.033
6. Bernier V, Lagacé M, Bichet DG, Bouvier M. Pharmacological chaperones: potential treatment for conformational diseases. Trends Endocrinol Metab 2004; 15:222-8; PMID:15223052; http://dx.doi.org/10.1016/j.tem.2004.05.003
7. Gaestel M, Alberti S. Molecular chaperones in health and disease. Berlin: Springer, 2006.
8. Yancey PH, Clark ME, Hand SC, Bowlus R D, Somero GN. Living with water stress: evolution of osmolyte systems. Science 1982; 217:1214-22; PMID:7112124; http://dx.doi.org/10.1126/science.7112124
9. Lin TY, Timasheff SN. Why do some organisms use a urea-methylamine mixture as osmolyte? Thermodynamic compensation of urea and tri-methylamine N-oxide interactions with protein. Biochemistry 1994; 33:12695-701; PMID:7918496; http://dx.doi.org/10.1021/bi00208a021
10. Baskakov I, Bolen DW. Forcing thermodynami-cally unfolded proteins to fold. J Biol Chem 1998; 273:4831-4; PMID:9478922; http://dx.doi.org/10.1074/jbc.273.9.4831
11. Street TO, Bolen DW, Rose GD. A molecular mechanism for osmolyte-induced protein stability. Proc Natl Acad Sci USA 2006; 103:13997-4002; PMID:16968772; http://dx.doi.org/10.1073/pnas.0606236103
12. Diamant S, Eliahu N, Rosenthal D, Goloubinoff P. Chemical chaperones regulate molecular chaper-ones in vitro and in cells under combined salt and heat stresses. J Biol Chem 2001; 276:39586-91; PMID:11517217; http://dx.doi.org/10.1074/jbc.M103081200
13. Street TO, Krukenberg KA, Rosgen J, Bolen DW, Agard DA. Osmolyte-induced conformational changes in the Hsp90 molecular chaperone. Protein Sci 2010; 19:57-65; PMID:19890989
14. Uversky VN, Li J, Fink AL. Trimethylamine-N-oxide-induced folding of alpha-synuclein. FEBS Lett 2001; 509:31-5; PMID:11734201; http://dx.doi.org/10.1016/S0014-5793(01)03121-0
15. Yang DS, Yip CM, Huang TH, Chakrabartty A, Fraser PE. Manipulating the amyloid-beta aggregation pathway with chemical chaperones. J Biol Chem 1999; 274:32970-4; PMID:10551864; http://dx.doi.org/10.1074/jbc.274.46.32970
16. Fung J, Darabie AA, McLaurin J. Contribution of simple saccharides to the stabilization of amyloid structure. Biochem Biophys Res Commun 2005; 328:1067-72; PMID:15707986; http://dx.doi.org/10.1016/j.bbrc.2005.01.068
17. Tatzelt J, Prusiner SB, Welch WJ. Chemical chaper-ones interfere with the formation of scrapie prion protein. EMBO J 1996; 15:6363-73; PMID:8978663
18. Gu Y, Singh N. Doxycycline and protein folding agents rescue the abnormal phenotype of familial CJD H187R in a cell model. Brain Res Mol Brain Res 2004; 123:37-44; PMID:15046864; http://dx.doi.org/10.1016/j.molbrainres.2004.01.006
19. Bennion BJ, DeMarco ML, Daggett V. Preventing misfolding of the prion protein by trimethyl-amine N-oxide. Biochemistry 2004; 43:12955-63; PMID:15476389; http://dx.doi.org/10.1021/bi0486379
20. Tanaka M, Machida Y, Niu S, Ikeda T, Jana NR, Doi H, Kurosawa M, Nekooki M, Nukina N. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 2004; 10:148-54; PMID:14730359; http://dx.doi.org/10.1038/nm985
21. Shaked GM, Engelstein R, Avraham I, Kahana E, Gabizon R. Dimethyl sulfoxide delays PrP sc accumulation and disease symptoms in prion-infected hamsters. Brain Res 2003; 983:137-43; PMID:12914974; http://dx.doi.org/10.1016/S0006-8993(03)03045-2
22. Dover GJ, Brusilow S, Charache S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 1994; 84:339-43; PMID:7517215
23. Camacho LH, Olson J, Tong WP, Young CW, Spriggs DR, Malkin MG. Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest New Drugs 2007; 25:131-8; PMID:17053987; http://dx.doi.org/10.1007/s10637-006-9017-4
24. Zeitlin PL, Diener-West M, Rubenstein RC, Boyle MP, Lee CK, Brass-Ernst L. Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther 2002; 6:119-26; PMID:12095312; http://dx.doi.org/10.1006/mthe.2002.0639
25. Wirth B, Brichta L, Hahnen E. Spinal muscular atrophy: from gene to therapy. Semin Pediatr Neurol 2006; 13:121-31; PMID:17027862; http://dx.doi.org/10.1016/j.spen.2006.06.008
26. Cudkowicz ME, Andres PL, Macdonald SA, Bedlack RS, Choudry R, Brown RH Jr., Zhang H, Schoenfeld DA, Shefner J, Matson S, et al.; Northeast ALS and National VA ALS Research Consortiums. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler 2009; 10:99-106; PMID:18688762; http://dx.doi.org/10.1080/17482960802320487
27. Gardian G, Browne SE, Choi DK, Klivenyi P, Gregorio J, Kubilus JK, Ryu H, Langley B, Ratan RR, Ferrante RJ, et al. Neuroprotective effects of phenyl-butyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 2005; 280:556-63; PMID:15494404
28. Zhou W, Bercury K, Cummiskey J, Luong N, Lebin J, Freed CR. Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease. J Biol Chem 2011; 286:14941-51; PMID:21372141; http://dx.doi.org/10.1074/jbc.M110.211029
29. Cuadrado-Tejedor M, García-Osta A, Ricobaraza A, Oyarzabal J, Franco R. Defining the mechanism of action of 4-phenylbutyrate to develop a small-molecule-based therapy for Alzheimer's disease. Curr Med Chem 2011; 18:5545-53; PMID:22172064; http://dx.doi.org/10.2174/092986711798347315
30. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, Görgün CZ, Hotamisligil GS. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006; 313:1137-40; PMID:16931765; http://dx.doi.org/10.1126/science.1128294
31. Mimori S, Ohtaka H, Koshikawa Y, Kawada K, Kaneko M, Okuma Y, Nomura Y, Murakami Y, Hamana H. 4-Phenylbutyric acid protects against neuronal cell death by primarily acting as a chemical chaperone rather than histone deacetylase inhibitor. Bioorg Med Chem Lett 2013; 23:6015-8; PMID:24044874; http://dx.doi.org/10.1016/j.bmcl.2013.08.001
32. Ren M, Leng Y, Jeong M, Leeds PR, Chuang DM. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem 2004; 89:1358-67; PMID:15189338; http://dx.doi.org/10.1111/j.1471-4159.2004.02406.x
33. Wright JM, Zeitlin PL, Cebotaru L, Guggino SE, Guggino WB. Gene expression profile analysis of 4-phenylbutyrate treatment of IB3-1 bronchial epithelial cell line demonstrates a major influence on heat-shock proteins. Physiol Genomics 2004; 16:204-11; PMID:14583596; http://dx.doi.org/10.1152/physiolgenomics.00160.2003
34. Konsoula Z, Barile FA. Epigenetic histone acetyla-tion and deacetylation mechanisms in experimental models of neurodegenerative disorders. J Pharmacol Toxicol Methods 2012; 66:215-20; PMID:22902970; http://dx.doi.org/10.1016/j.vascn.2012.08.001
35. Inden M, Kitamura Y, Takeuchi H, Yanagida T, Takata K, Kobayashi Y, Taniguchi T, Yoshimoto K, Kaneko M, Okuma Y, et al. Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J Neurochem 2007; 101:1491-504; PMID:17459145; http://dx.doi.org/10.1111/j.1471-4159.2006.04440.x
36. Cuadrado-Tejedor M, Ricobaraza AL, Torrijo R, Franco R, Garcia-Osta A. Phenylbutyrate is a mul-tifaceted drug that exerts neuroprotective effects and reverses the Alzheimer×s disease-like phenotype of a commonly used mouse model. Curr Pharm Des 2013; 19:5076-84; PMID:23448463; http://dx.doi.org/10.2174/1381612811319280006
37. Wiley JC, Meabon JS, Frankowski H, Smith EA, Schecterson LC, Bothwell M, Ladiges WC. Phenylbutyric acid rescues endoplasmic reticulum stress-induced suppression of APP proteolysis and prevents apoptosis in neuronal cells. PLoS One 2010; 5: e9135; PMID:20161760; http://dx.doi.org/10.1371/journal.pone.0009135
38. Ricobaraza A, Cuadrado-Tejedor M, Garcia-Osta A. Long-term phenylbutyrate administration prevents memory deficits in Tg2576 mice by decreasing Abeta. Front Biosci (Elite Ed) 2011; 3:1375-84; PMID:21622143
39. Wiley JC, Pettan-Brewer C, Ladiges WC. Phenylbutyric acid reduces amyloid plaques and rescues cognitive behavior in AD transgenic mice. Aging Cell 2011; 10:418-28; PMID:21272191; http://dx.doi.org/10.1111/j.1474-9726.2011.00680.x
40. Roy A, Ghosh A, Jana A, Liu X, Brahmachari S, Gendelman HE, Pahan K. Sodium phenylbutyr-ate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson's disease. PLoS One 2012; 7:e38113; PMID:22723850; http://dx.doi.org/10.1371/journal.pone.0038113
41. Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K, Kowall NW, Ratan RR, Luthi-Carter R, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neu-rodegenerative phenotype in Huntington's disease mice. J Neurosci 2003; 23:9418-27; PMID:14561870
42. Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S, Mahal A, Lowden PA, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 2003; 100:2041-6; PMID:12576549; http://dx.doi.org/10.1073/pnas.0437870100
43. Hogarth P, Lovrecic L, Krainc D. Sodium phenylbu-tyrate in Huntington's disease: a dose-finding study. Mov Disord 2007; 22:1962-4; PMID:17702032; http://dx.doi.org/10.1002/mds.21632
44. Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WC. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci USA 2002; 99:10671-6; PMID:12149470; http://dx.doi.org/10.1073/pnas.162362299
45. Ramalho RM, Viana RJ, Low WC, Steer CJ, Rodrigues CM. Bile acids and apoptosis modulation: an emerging role in experimental Alzheimer's disease. Trends Mol Med 2008; 14:54-62; PMID:18218342; http://dx.doi.org/10.1016/j.molmed.2007.12.001
46. Geier A, Wagner M, Dietrich CG, Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta 2007; 1773:283-308; PMID:17291602; http://dx.doi.org/10.1016/j.bbamcr.2006.04.014
47. Rodrigues CM, Fan G, Wong PY, Kren BT, Steer CJ. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochon-drial transmembrane potential and reactive oxygen species production. Mol Med 1998; 4:165-78; PMID:9562975
48. Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998; 101:2790-9; PMID:9637713; http://dx.doi.org/10.1172/JCI1325
49. Rodrigues CM, Solá S, Sharpe JC, Moura JJ, Steer CJ. Tauroursodeoxycholic acid prevents Bax-induced membrane perturbation and cytochrome C release in isolated mitochondria. Biochemistry 2003; 42:3070-80; PMID:12627974; http://dx.doi.org/10.1021/bi026979d
50. Azzaroli F, Mehal W, Soroka CJ, Wang L, Lee J, Crispe IN, Boyer JL. Ursodeoxycholic acid diminishes Fas-ligand-induced apoptosis in mouse hepatocytes. Hepatology 2002; 36:49-54; PMID:12085348; http://dx.doi.org/10.1053/jhep.2002.34511
51. Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P. Bile acids as regulatory molecules. J Lipid Res 2009; 50:1509-20; PMID:19346331; http://dx.doi.org/10.1194/jlr.R900007-JLR200
52. Song S, Liang JJ, Mulhern ML, Madson CJ, Shinohara T. Cholesterol-derived bile acids enhance the chaperone activity of α-crystallins. Cell Stress Chaperones 2011; 16:475-80; PMID:21380614; http://dx.doi.org/10.1007/s12192-011-0259-5
53. Berger E, Haller D. Structure-function analysis of the tertiary bile acid TUDCA for the resolution of endoplasmic reticulum stress in intestinal epithelial cells. Biochem Biophys Res Commun 2011; 409:610-5; PMID:21605547; http://dx.doi.org/10.1016/j.bbrc.2011.05.043
54. de Almeida SF, Picarote G, Fleming J V, Carmo-Fonseca M, Azevedo JE, de Sousa M. Chemical chaperones reduce endoplasmic reticulum stress and prevent mutant HFE aggregate formation. J Biol Chem 2007; 282:27905-12; PMID:17626021; http://dx.doi.org/10.1074/jbc.M702672200
55. Viana RJ, Nunes AF, Castro RE, Ramalho RM, Meyerson J, Fossati S, Ghiso J, Rostagno A, Rodrigues CM. Tauroursodeoxycholic acid prevents E22Q Alzheimer's Abeta toxicity in human cerebral endothelial cells. Cell Mol Life Sci 2009; 66:1094-104; PMID:19189048; http://dx.doi.org/10.1007/s00018-009-8746-x
56. Kim NH, Choi JK, Jeong BH, Kim JI, Kwon MS, Carp RI, Kim YS. Effect of transition metals (Mn, Cu, Fe) and deoxycholic acid (DA) on the conversion of PrPC to PrPres. FASEB J 2005; 19:783-5; PMID:15758042
57. Macedo B, Batista AR, Ferreira N, Almeida MR, Saraiva MJ. Anti-apoptotic treatment reduces trans-thyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy. Biochim Biophys Acta 2008; 1782:517-22; PMID:18572024; http://dx.doi.org/10.1016/j.bbadis.2008.05.005
58. Nunes AF, Amaral JD, Lo AC, Fonseca MB, Viana RJ, Callaerts-Vegh Z, D'Hooge R, Rodrigues CM. TUDCA, a bile acid, attenuates amyloid precursor protein processing and amyloid-β deposition in APP/PS1 mice. Mol Neurobiol 2012; 45:440-54; PMID:22438081; http://dx.doi.org/10.1007/s12035-012-8256-y
59. Castro-Caldas M, Carvalho AN, Rodrigues E, Henderson CJ, Wolf CR, Rodrigues CM, Gama MJ. Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson's disease. Mol Neurobiol 2012; 46:475-86; PMID:22773138; http://dx.doi.org/10.1007/s12035-012-8295-4
60. Castro RE, Solá S, Ramalho RM, Steer CJ, Rodrigues CM. The bile acid tauroursodeoxycholic acid modulates phosphorylation and translocation of bad via phosphatidylinositol 3-kinase in glutamate-induced apoptosis of rat cortical neurons. J Pharmacol Exp Ther 2004; 311:845-52; PMID:15190125; http://dx.doi.org/10.1124/jpet.104.070532
61. Kuwata K, Nishida N, Matsumoto T, Kamatari YO, Hosokawa-Muto J, Kodama K, Nakamura HK, Kimura K, Kawasaki M, Takakura Y, et al. Hot spots in prion protein for pathogenic conversion. Proc Natl Acad Sci USA 2007; 104:11921-6; PMID:17616582; http://dx.doi.org/10.1073/pnas.0702671104
62. Hosokawa-Muto J, Kamatari YO, Nakamura HK, Kuwata K. Variety of antiprion compounds discovered through an in silico screen based on cellular-form prion protein structure: Correlation between anti-prion activity and binding aff inity. Antimicrob A gents Chemother 2009; 53:765-71; PMID:19015328; http://dx.doi.org/10.1128/AAC.01112-08
63. Katsuno M, Tanaka F, Sobue G. Perspectives on molecular targeted therapies and clinical trials for neurodegenerative diseases. J Neurol Neurosurg Psychiatry 2012; 83:329-35; PMID:22323772; http://dx.doi.org/10.1136/jnnp-2011-301307
64. Ferreira NC, Marques IA, Conceição WA, Macedo B, Machado CS, Mascarello A, Chiaradia-Delatorre LD, Yunes RA, Nunes RJ, Hughson AG, et al. Anti-prion activity of a panel of aromatic chemical compounds: in vitro and in silico approaches. PLoS One 2014; 9: e84531; PMID:24400098; http://dx.doi.org/10.1371/journal.pone.0084531